To raise mesothelioma awareness and honor everyone affected by this aggressive cancer, Novocure is leading an initiative called Light the World Blue. For the second consecutive year, we’ve arranged for buildings and landmarks in U.S. cities to light blue, the official color of mesothelioma awareness, on Sept. 26.
Noam Zaradez, a Device Support Specialist Regional Manager and Care Coordinator in Israel, initiated a monthly group therapy session for his team after realizing the importance of processing emotions related to working with patients who have glioblastoma.
Professor Ignace Vergote conducts 20 ovarian cancer trials per year and has authored more than 800 papers in gynecologic cancers. He was an investigator in Novocure’s phase 2 pilot trial in recurrent ovarian cancer, INNOVATE.
Tobias Weizel, Novocure’s General Manager Germany, leads the company’s commercial business in Germany and said he feels lucky to be a part of Novocure’s mission of bringing a profoundly different cancer treatment to patients worldwide.
Our Device Support Specialists (DSSs) work one-on-one with patients — educating them about the device, and providing technical support and personal contact with Novocure. Learn more about Amy Luton, one of our DSSs in Texas.
Our second generation Optune System is smaller and less than half the weight of our first generation Optune System. See more on the innovation behind our redesigned Tumor Treating Fields delivery system.
novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.